Associated Papers
Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.
Jansche R et al.
Cell Death & Disease, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
High-throughput evaluation of genetic variants with prime editing sensor libraries.
Gould SI et al.
Nature Biotechnology, 2025
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
Implementing Massive Parallel Sequencing into Biliary Samples Obtained through Endoscopic Retrograde Cholangiopancreatography for Diagnosing Malignant Bile Duct Strictures.
Park W et al.
International Journal of Molecular Sciences, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.
Choe JH et al.
Cancer Discovery, 2023
Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.
Haefliger S et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC.
Cooper AJ et al.
Jto Clinical and Research Reports, 2022
Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q et al.
Acta Neurochirurgica, 2022
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.
Burkhardt B et al.
Nature Communications, 2022
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.
Li Z et al.
Npj Breast Cancer, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.
Catherwood MA et al.
Frontiers in Oncology, 2022
Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients.
Siraj AK et al.
Hereditary Cancer in Clinical Practice, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Deek MP et al.
European Urology, 2021
Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
Reza MN et al.
Scientific Reports, 2021
A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database.
Pappula AL et al.
Cancers, 2021
Analysis and Interpretation of the Impact of Missense Variants in Cancer.
Petrosino M et al.
International Journal of Molecular Sciences, 2021
The genetic landscape of choroid plexus tumors in children and adults.
Thomas C et al.
Neuro-oncology, 2021
Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study.
Zhang H et al.
Oncology Letters, 2021
p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
Gencel-Augusto J et al.
Genes & Development, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
BRAF AMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF V600E.
Da R et al.
Frontiers in Oncology, 2020
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer.
Coco S et al.
Cancers, 2019
Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers.
Katz C et al.
Genes & Development, 2018
A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer.
Viel A et al.
Ebiomedicine, 2017
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2017
Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P et al.
International Journal of Cancer, 2016
Tetramer formation of tumor suppressor protein p53: Structure, function, and applications.
Kamada R et al.
Biopolymers, 2016
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Weisman PS et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2016
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W et al.
Nature Genetics, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K et al.
Oncotarget, 2012
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R et al.
The Journal of Biological Chemistry, 2011
Ethnic differences and functional analysis of MET mutations in lung cancer.
Krishnaswamy S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Evaluation of transcriptional activity of p53 in individual living mammalian cells.
Imagawa T et al.
Analytical Biochemistry, 2009
The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T et al.
Oncogene, 2005
Molecular genetics and diversity of choroid plexus tumors.
Thomas C et al.
Neuro-oncology Advances, 0